银屑病关节炎患者的慢性肾脏病:一项队列研究
该前瞻性观察队列纳入1336例银屑病关节炎患者,慢性肾脏病(CKD)患病率为9.2%(123/1336),其中79.7%在随访期间新发。多变量Cox回归显示糖尿病、肾结石、影像学关节破坏计数、尿酸及每日使用非甾体抗炎药与CKD发生独立相关,甲氨蝶呤使用似有保护作用。
要点
- 银屑病关节炎患者中CKD并不少见,本队列患病率为9.2%(123/1336)。
- 新发CKD与糖尿病、肾结石、关节破坏、尿酸升高及每日NSAID使用独立相关。
- 甲氨蝶呤使用与CKD发生风险降低独立相关(HR 0.51,p=0.01)。
核心结论
- CKD在银屑病关节炎患者中并不少见,其发生与相关合并症、关节破坏及NSAID使用相关,甲氨蝶呤似乎具有保护作用。
研究设计与样本
- 前瞻性观察队列研究,纳入本队列随访的1336例银屑病关节炎患者,CKD定义为估算肾小球滤过率(eGFR)<60 mL/min/1.73 m2持续至少3个月。
主要发现
- 1336例患者中123例(9.2%)患CKD,其中25例(20.3%)在入组时即有CKD,98例(79.7%)在随访期间新发CKD,新发距基线中位(IQR)8.2(2.8-14.0)年。
- 98例新发CKD患者中18例(18.3%)基线肌酐翻倍,49例(50%)出现基线eGFR持续下降≥40%,2例出现eGFR<15 mL/min/1.73 m2。
- 调整入组年龄、性别和基线eGFR的多变量Cox回归中,与CKD发生独立相关的因素包括糖尿病(HR 2.58,p<0.001)、肾结石(HR 2.14,p=0.01)、影像学破坏关节计数(HR 1.02,p=0.02)、尿酸(每增加50单位,HR 1.21,p<0.001)、每日使用非甾体抗炎药(NSAIDs)(HR 1.77,p=0.02)及甲氨蝶呤使用(HR 0.51,p=0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Chronic kidney disease (CKD) is a comorbidity in psoriatic arthritis (PsA). We aimed to define the prevalence of CKD in patients with PsA, describe their long-term renal outcomes and identify risk factors for CKD development. METHODS: We included patients with PsA followed by our prospective observational cohort. We defined CKD as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 for at least 3 months. We characterised long-term renal outcomes of CKD cases identified following clinic entry. We used time-dependent Cox regression models to identify factors associated with CKD development. RESULTS: Of 1336 patients included in the study, 123 (9.2%) had CKD. Of these, 25 (20.3%) were observed to have CKD at clinic entry and 98 (79.7%) developed CKD during follow-up at a median (IQR) of 8.2 (2.8-14.0) years from baseline. Doubling of baseline creatinine was observed in 18 of 98 (18.3%) new patients with CKD. 49 (50%) patients developed a sustained ≥40% reduction in baseline eGFR. Two patients developed eGFR <15 mL/min/1.73 m2. In the multivariate Cox regression model adjusted for age at study entry, sex and baseline eGFR, factors independently associated with the development of CKD included diabetes mellitus (HR 2.58, p<0.001), kidney stones (HR 2.14, p=0.01), radiographic damaged joint count (HR 1.02, p=0.02), uric acid (HR 1.21, p<0.001; 50-unit increase), daily use of non-steroidal anti-inflammatory drugs (NSAIDs) (HR 1.77, p=0.02) and methotrexate use (HR 0.51, p=0.01). CONCLUSION: CKD is not infrequent in PsA. Its development is associated with related comorbidities, joint damage and NSAID use. Methotrexate seems to be protective.
引用
- Kharouf F, Gao S, Al-Matar S, et al. Chronic kidney disease in patients with psoriatic arthritis: a cohort study. RMD Open. 2024. PMID: 39510763. doi:10.1136/rmdopen-2024-004636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。